Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 18444843.
- Also identified by DOI 10.1086/533469.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM(197) conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.
Medical subject headings
- Guillain-Barre Syndrome
- Meningococcal Vaccines